- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Brimonidine Tartrate Ophthalmic Solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 2 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,000
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Allergic Conjunctivitis
- Interventions
- Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
- Drug
- Lead sponsor
- Fovea Pharmaceuticals SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Allergic Conjunctivitis
- Interventions
- Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee + 1 more
- Conditions
- Wound Heal
- Interventions
- Timolol 0.25% Ophthalmic Solution, Standard Wound Care
- Drug · Other
- Lead sponsor
- Keith G. LeBlanc, Jr, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Metairie, Louisiana
- Conditions
- Dry Eye
- Interventions
- Lifitegrast
- Drug
- Lead sponsor
- MDbackline, LLC
- Other
- Eligibility
- Not listed
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Laguna Hills, California
- Conditions
- Visual Acuity
- Interventions
- Blink® Tears eye drops in a multidose bottle, Preservative-free investigational lubricating eye drops in a Novelia® eyedropper
- Drug
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Maitland, Florida • Tyler, Texas
- Conditions
- Thyroid Eye Disease, Ocular Hypertension, Glaucoma
- Interventions
- Prostaglandin Analog, Timolol
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Ocular Pain
- Interventions
- TetraLens bandage contact lens, Control Acuvue Oasys Bandage contact Lens
- Drug · Device
- Lead sponsor
- Vance Thompson Vision
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
- Drug · Device
- Lead sponsor
- SpyGlass Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Primary Open-angle Glaucoma
- Interventions
- Patient Educational Intervention, Usual Care, Ophthalmologist Educational Intervention
- Other
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Meibomian Gland Dysfunction
- Interventions
- testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
- Drug
- Lead sponsor
- ORA, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Presbyopia
- Interventions
- Pilocarpine HCl Ophthalmic Solution, Vehicle
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Prescott, Arizona • Sun City, Arizona + 30 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- TL-925, Placebo
- Drug
- Lead sponsor
- Telios Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Allergic Conjunctivitis
- Interventions
- TL-925, Placebo
- Drug
- Lead sponsor
- Telios Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Keratoconus, Corneal Ectasia
- Interventions
- Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light
- Combination Product
- Lead sponsor
- Price Vision Group
- Industry
- Eligibility
- 10 Years to 90 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Glaucoma
- Interventions
- Educational - glaucoma, Dose monitoring and reminder, Educational - general, Dose monitoring
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- TRS01 eye drops
- Drug
- Lead sponsor
- Tarsier Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Palisades Park, New Jersey • San Antonio, Texas
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Cataract, Anterior Chamber Inflammation, Pain, Postoperative
- Interventions
- Dexamethasone phosphate, Placebo
- Combination Product · Other
- Lead sponsor
- Eyegate Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Dry Eye
- Interventions
- Artificial tears
- Drug
- Lead sponsor
- Hom, Milton M., OD, FAAO
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Azusa, California
- Conditions
- Glaucoma, Open-Angle
- Interventions
- H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
- Drug
- Lead sponsor
- Allysta Pharmaceutical
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Goose Creek, South Carolina
- Conditions
- Keratoconus, Post-Refractive Ectasia
- Interventions
- Riboflavin, UVX light
- Drug · Device
- Lead sponsor
- Price Vision Group
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Dry Eye Disease, Endothelial Cell
- Interventions
- Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
- Drug
- Lead sponsor
- Novaliq GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Torrance, California • Garner, North Carolina + 3 more